*TARGET PGB (PEPTIDOGLYCAN BIOSYNTHESIS) IS THE FOCUS OF COLLABORATION
DESIGNED TO DEVELOP NOVEL FAMILY OF ANTIBACTERIAL DRUGS BASED ON HIGHLY
Hamburg, Germany and Cambridge, MA - 16 May 2013: Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.
- STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY - EVOTEC'S DRUG DISCOVERY PLATFORM GENERATES GROWTH
- NEW HORMONE IDENTIFIED AS PART OF THE CUREBETA INITIATIVE
- GUIDANCE 2013 CONFIRMED
Hamburg, Germany - 14 May 2013: Evotec AG today reported financial results and corporate updates for the first quarter of 2013.- read more
Hamburg, Germany and Boston, MA - 30 April 2013: The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.- read more